Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna.
Aimillios LallasElvira MoscarellaHarald KittlerCaterina LongoLuc ThomasI ZalaudekAthanassios KyrgidisSofia-Magdalini ManoliNicola Di MeoChryssoula PapageorgiouZoi ApallaGiuseppe ArgenzianoPublished in: The British journal of dermatology (2021)